(Q45865821)

17 December 2017

title

In vivo bypass of hemophilia A coagulation defect by factor XIIa implant (English)

1 reference

17 December 2017

0 references

0 references

Ton-That TT

1

1 reference

17 December 2017

Doron D

2

1 reference

17 December 2017

Pollard BS

3

1 reference

17 December 2017

Bacher J

4

1 reference

17 December 2017

Pollard HB

5

1 reference

17 December 2017

publication date

1 March 2000

1 reference

17 December 2017

published in

Nature Biotechnology

1 reference

17 December 2017

volume

18

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

289-295

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/73727

exact match

0 references

cites work

Hemophilia treatment in historical perspective: a review of medical and social developments

1 reference

Complications of hemophilia A treatment: factor VIII inhibitors

21 January 2018

1 reference

Antihemophilic factor inhibitors. Management with prothrombin complex concentrates

21 January 2018

1 reference

Activated prothrombin concentrate for patients with factor VIII inhibitors

21 January 2018

1 reference

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

21 January 2018

1 reference

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

21 January 2018

1 reference

A therapeutic alternative for haemophiliacs with inhibitors

21 January 2018

1 reference

Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor

21 January 2018

1 reference

Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor

21 January 2018

1 reference

Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease

21 January 2018

1 reference

Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor

21 January 2018

1 reference

Letter: Factor-VIII inhibitor bypassing activity

21 January 2018

1 reference

A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo

21 January 2018

1 reference

Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor).

21 January 2018

1 reference

Perspectives in diabetes. Islet transplantation with immunoisolation

21 January 2018

1 reference

Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation

21 January 2018

1 reference

The management of hemophilia patients with inhibitors

21 January 2018

1 reference

7 January 2021

By what mechanisms could prothrombin complex concentrates promote factor VIII bypassing activity in vivo?

1 reference

7 January 2021

Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report.

1 reference

7 January 2021

Experiences with recombinant factor VIIa in haemophiliacs

1 reference

7 January 2021

Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.

1 reference

7 January 2021

Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor)

1 reference

7 January 2021

The molecular biology of initiation of coagulation by tissue factor

1 reference

7 January 2021

Factor VIIa in the treatment of haemophilia.

1 reference

7 January 2021

Islet transplantation using an immunoprotective membrane in dogs that have undergone a pancreatectomy

1 reference

7 January 2021

Identifiers

DOI

10.1038/73727

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017